Protagonist Therapeutics (PTGX) Price & Analysis

Compare

733 Followers

PTGX Stock Chart & Stats

$85.59

-$0.87(-2.26%)

At close: Jan 08 4:00 PM EST

$85.59

-$0.87(-2.26%)

Day’s Range― - ―

52-Week Range$33.70 - $96.54

Previous CloseN/A

Volume120.35K

Average Volume (3M)675.76K

Market Cap

$5.19B

Enterprise Value$5.25B

Total Cash (Recent Filing)$576.12M

Total Debt (Recent Filing)$10.75M

Price to Earnings (P/E)135.1

Beta0.18

Next Earnings

Mar 18, 2026

EPS Estimate

-0.33

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.62

Shares Outstanding62,515,667

10 Day Avg. Volume710,669

30 Day Avg. Volume675,758

Financial Highlights & Ratios

PEG Ratio-0.02

Price to Book (P/B)3.52

Price to Sales (P/S)5.47

P/FCF Ratio13.00

Enterprise Value/Market Cap1.01

Enterprise Value/Revenue25.08

Enterprise Value/Gross Profit25.08

Enterprise Value/Ebitda190.62

Forecast

1Y Price Target

$96.20

Price Target Upside12.40% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering11

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Data StrengthLate-stage results and extension data showed durable control of hematocrit, a safety profile comparable to placebo, and high patient adherence, bolstering the case for regulatory approval and physician adoption.

Partnership And Royalty StructureSubmission of a regulatory application in collaboration with a global pharmaceutical partner establishes U.S. profit sharing and partner-led international commercialization, creating multiple pathways to monetize the lead drug through royalties and milestone payments.

Pipeline Expansion And PartneringAdvancement of oral multi-receptor obesity candidates, an oral IL‑17 program, and additional early-stage assets broadens the pipeline and increases appeal for licensing or co-development deals that could unlock value.

Bears Say

Analyst Report ConflictsDisclosed business ties between the analyst's firm and covered companies raise questions about report objectivity, which could influence investor interpretation and market reaction.

Opt-out Financial ObligationsA contractual opt-out decision could require substantial opt-out and milestone payments, increasing near-term financial obligations and pressuring liquidity.

Strategic Decision UncertaintyA limited decision window to exercise opt-out rights introduces strategic uncertainty that could complicate partner negotiations and create valuation volatility.

Protagonist Therapeutics News

Protagonist Therapeutics price target raised to $117 from $80 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Protagonist Therapeutics (PTGX) to $117 from $80 and keeps a...

5d ago

PTGX

Protagonist Therapeutics: Advancing Multi-Asset Inflammation and Obesity Pipeline with Strong Cash Runway Supports Buy Rating

Analyst Yun Zhong of Wedbush maintained a Buy rating on Protagonist Therapeutics, boosting the price target to $86.00....

23d ago

PTGX

Protagonist Therapeutics Highlights Diversified Pipeline and Partnerships

Protagonist Therapeutics ( ($PTGX) ) has issued an update. On January 12, 2026, Protagonist Therapeutics released an updated...

23d ago

PTGX

Advancing, De-Risked Pipeline and Near-Term Regulatory Catalysts Underpin Protagonist Therapeutics Buy Rating

Analyst Yun Zhong from Wedbush maintained a Buy rating on Protagonist Therapeutics and keeping the price target at...

29d ago

PTGX

Protagonist Therapeutics price target raised to $110 from $88 at Truist

Truist raised the firm’s price target on Protagonist Therapeutics (PTGX) to $110 from $88 and keeps a Buy...

1M ago

PTGX

Takeda, Protagonist Therapeutics submit rusfertide new drug application to FDA

Takeda (TAK) and Protagonist Therapeutics (PTGX) announced the submission of a new drug application to the FDA seeking...

1M ago

TAK

PTGX

Protagonist Therapeutics price target raised to $108 from $88 at Barclays

Barclays raised the firm’s price target on Protagonist Therapeutics (PTGX) to $108 from $88 and keeps an Overweight...

2M ago

PTGX

Promising Clinical Data and Strategic Collaborations Drive Buy Rating for Protagonist Therapeutics

In a report released today, Yun Zhong from Wedbush maintained a Buy rating on Protagonist Therapeutics, with a...

2M ago

PTGX

Protagonist Therapeutics price target raised to $115 from $98 at Citi

Citi raised the firm’s price target on Protagonist Therapeutics (PTGX) to $115 from $98 and keeps a Buy...

2M ago

PTGX

Protagonist, Takeda present longer-term data at ASH 2025 on rusfertide

Protagonist Therapeutics (PTGX) and Takeda (TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study...

2M ago

TAK

PTGX

Protagonist Therapeutics price target raised to $65 from $47 at Goldman Sachs

Goldman Sachs raised the firm’s price target on Protagonist Therapeutics (PTGX) to $65 from $47 and keeps a...

3M ago

PTGX

Protagonist Therapeutics price target raised to $98 from $96 at Citi

Citi raised the firm’s price target on Protagonist Therapeutics (PTGX) to $98 from $96 and keeps a Buy...

3M ago

PTGX

Protagonist Therapeutics price target raised to $81 from $68 at JPMorgan

JPMorgan analyst Brian Cheng raised the firm’s price target on Protagonist Therapeutics (PTGX) to $81 from $68 and...

3M ago

PTGX

Protagonist Therapeutics price target raised to $88 from $72 at Barclays

Barclays raised the firm’s price target on Protagonist Therapeutics (PTGX) to $88 from $72 and keeps an Overweight...

3M ago

PTGX

PTGX FAQ

What was Protagonist Therapeutics’s price range in the past 12 months?

Protagonist Therapeutics lowest stock price was $33.70 and its highest was $96.54 in the past 12 months.

What is Protagonist Therapeutics’s market cap?

Protagonist Therapeutics’s market cap is $5.19B.

When is Protagonist Therapeutics’s upcoming earnings report date?

Protagonist Therapeutics’s upcoming earnings report date is Mar 18, 2026 which is in 42 days.

How were Protagonist Therapeutics’s earnings last quarter?

Protagonist Therapeutics released its earnings results on Nov 06, 2025. The company reported -$0.62 earnings per share for the quarter, beating the consensus estimate of -$0.627 by $0.007.

Is Protagonist Therapeutics overvalued?

According to Wall Street analysts Protagonist Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Protagonist Therapeutics pay dividends?

Protagonist Therapeutics does not currently pay dividends.

What is Protagonist Therapeutics’s EPS estimate?

Protagonist Therapeutics’s EPS estimate is -0.33.

How many shares outstanding does Protagonist Therapeutics have?

Protagonist Therapeutics has 62,515,667 shares outstanding.

What happened to Protagonist Therapeutics’s price movement after its last earnings report?

Protagonist Therapeutics reported an EPS of -$0.62 in its last earnings report, beating expectations of -$0.627. Following the earnings report the stock price went down -0.301%.

Which hedge fund is a major shareholder of Protagonist Therapeutics?

Currently, no hedge funds are holding shares in PTGX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Protagonist Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

7.80%

Trailing 12-Months

Asset Growth

16.20%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Protagonist Therapeutics

Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Protagonist Therapeutics (PTGX) Earnings & Revenues

Historic Earnings Reports

PTGX Stock 12 Month Forecast

Average Price Target

$96.20

▲(12.40% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"36":"$36","77":"$77","118":"$118","56.5":"$56.5","97.5":"$97.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":117,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$117.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":96.2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$96.20</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":65,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$65.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[36,56.5,77,97.5,118],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,83.05,85.66153846153846,88.27307692307691,90.88461538461539,93.49615384615385,96.1076923076923,98.71923076923076,101.33076923076922,103.9423076923077,106.55384615384615,109.16538461538461,111.77692307692308,114.38846153846154,{"y":117,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,83.05,84.06153846153846,85.07307692307693,86.08461538461539,87.09615384615384,88.1076923076923,89.11923076923077,90.13076923076923,91.1423076923077,92.15384615384616,93.16538461538462,94.17692307692307,95.18846153846154,{"y":96.2,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,83.05,81.66153846153846,80.27307692307691,78.88461538461539,77.49615384615385,76.1076923076923,74.71923076923076,73.33076923076923,71.9423076923077,70.55384615384615,69.16538461538461,67.77692307692308,66.38846153846154,{"y":65,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":37.8,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.59,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.88,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.99,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.15,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.21,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.83,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.85,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78.62,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.64,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":87.34,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":83.05,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >